Dabrafenib (GSK2118436)

For research use only. Not for use in humans.

目录号：S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
10mg	RMB 1056.75	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献150篇：

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )
Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )
Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )
Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )
Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )
J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	M3G4[2tqdmG\|ZTDBd5NigQ>?				NWmySIo3UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BETEN\|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN	NXPvO\|hNOjR7MEC2O\|M>
SK-MEL-28	M1jSZ2tqdmG\|ZTDBd5NigQ>?		M37sZVEhcA>?		M{Xo[GlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2=	NH3tN4gzPDlyME[3Ny=>
HepG2	NI\pSWlMcW6jc3WgRZN{[Xl?				MXHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0>	MXyyOFkxODZ5Mx?=
COLO205	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTiTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch\|ryP	NWWyXHc3OjR7MEC2O\|M>
HepG2	NVXjTXZTTnWwY4Tpc44hSXO\|YYm=		M1X4TVQ2KG2rbh?=	MXnEUXNQ	MYjJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	M4K3XFI1QTByNkez
HFF	NH;s[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxNEDPxE1?	MnjmO\|IhcA>?	MYnEUXNQ	MXTJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN	Mnn5NlM5PDRyM{i=
SK-MEL-28	NUXNc5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPue2FwOTBizszN	M1j3S\|czKGh?	M3fUXWROW09?	MmLlTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR\|IN88US=>	M3;RVlI{QDR2MEO4
A375P-F11	M4LFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xNEDPxE1?	M4fwdVczKGh?	MUDEUXNQ	NELmTGFKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO	NYHYXI5xOjN6NESwN\|g>
MALME-3M	NIT6[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrwfoQyOCEQvF2=	MUC3NkBp	MnnmSG1UVw>?	Mof2TWM2OD1zIH7N	NFfBW20zOzh2NECzPC=>
UACC-62	M3Hpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT1[G0yOCEQvF2=	NETN[o44OiCq	MUTEUXNQ	MYnJR\|UxRTFibl2=	MWqyN\|g1PDB\|OB?=
C32TG	NXr5PZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi0VJRHOTBizszN	MkfLO\|IhcA>?	M2iyemROW09?	MXvJR\|UxRTFibl2=	M3;r[\|I{QDR2MEO4
SK-MEL-1	M2fzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\EWlExKM7:TR?=	NUm4eFFZPzJiaB?=	MYTEUXNQ	M4LGUWlEPTB;MjDuUS=>	NF\WZlYzOzh2NECzPC=>
M14	NVKydYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3izd\|ExKM7:TR?=	MkTRO\|IhcA>?	MnSzSG1UVw>?	MlriTWM2OD1{IH7N	NWrGdYl5OjN6NESwN\|g>
SK-MEL-28	NWn0e4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	MX:3NkBp	MUjEUXNQ	NWjxb2FtUUN3ME2zJI5O	M1PjcVI{QDR2MEO4
A375	M3LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnpSpo6OTBizszN	NGjkPZU4OiCq	MlXtSG1UVw>?	MlL0TWM2OD12IH7N	NHXFPI4zOzh2NECzPC=>
DU-4475	M4rKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	M1vld\|czKGh?	M2fzV2ROW09?	NVTTNXVIUUN3ME21JI5O	MV:yN\|g1PDB\|OB?=
UACC-257	NXjXU5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rRNFExKM7:TR?=	NH7zWFI4OiCq	MnHFSG1UVw>?	M1;KUGlEPTB;NjDuUS=>	MXWyN\|g1PDB\|OB?=
Colo 205	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFe2cXYyOCEQvF2=	NUP2OHdrPzJiaB?=	M2eydmROW09?	MnT5TWM2OD15IH7N	NIK0[XgzOzh2NECzPC=>
SK-MEL-3	M3S1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3Wd2wyOCEQvF2=	MnnZO\|IhcA>?	Mk\KSG1UVw>?	M1fpNmlEPTB;NzDuUS=>	MXWyN\|g1PDB\|OB?=
SH-4	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXLOZkyOCEQvF2=	NWHwdYZyPzJiaB?=	MlrWSG1UVw>?	MnHpTWM2OD16IH7N	NYDFUFFuOjN6NESwN\|g>
A101D	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zGOVExKM7:TR?=	M3jocFczKGh?	NYfiVmdGTE2VTx?=	MWjJR\|UxRTlibl2=	NUjseo5{OjN6NESwN\|g>
ES-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO3XIEyOCEQvF2=	MXe3NkBp	MonHSG1UVw>?	NF7Mc4tKSzVyPUWzJI5O	NEHxTm4zOzh2NECzPC=>
HT-29	NWDSdoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWixNEDPxE1?	Ml7iO\|IhcA>?	NYTXRm53TE2VTx?=	NET3coxKSzVyPU[2JI5O	MVWyN\|g1PDB\|OB?=
SW1417	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG4NVAh\|ryP	M2W5O\|czKGh?	NIm5cWtFVVOR	MUnJR\|UxRTF3ODDuUS=>	Mof2NlM5PDRyM{i=
SW872	NEfPdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f1R\|ExKM7:TR?=	MWW3NkBp	M4q0RmROW09?	NVfFWnVuUUN3ME2zO\|chdk1?	NF3BNoMzOzh2NECzPC=>
RKO	NX7obWJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP4NVAh\|ryP	MY[3NkBp	NVHtOZdKTE2VTx?=	NVnpVoZ1UUN3ME2yMlUzOiEQvF2=	Ml3BNlM5PDRyM{i=
A673	M1LJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLsNVAh\|ryP	NG\qWI44OiCq	MYHEUXNQ	M2jsUWlEPTB;MUCg{txO	NVvIc\|h3OjN6NESwN\|g>
GCT	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxNEDPxE1?	NGHRPW44OiCq	M2qwN2ROW09?	NIXiUHZKSzVyPUGwJO69VQ>?	NUiw[\|FEOjN6NESwN\|g>
WM-115	MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fXXVExKM7:TR?=	MVG3NkBp	M2TYbmROW09?	M333Z2lEPTB;NTDuUS=>	NFHWbGYzOzh2NECzPC=>
YUMAC	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nVXVExKM7:TR?=	NXTPVHlMPzJiaB?=	MnzVSG1UVw>?	NH\JNolKSzVyPUWgcm0>	MX[yN\|g1PDB\|OB?=
OV-90	M{fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDRe2kyOCEQvF2=	MXm3NkBp	MWHEUXNQ	M4jVc2lEPTB;Mkmgcm0>	M4m4T\|I{QDR2MEO4
NCI-H508	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKxNEDPxE1?	NGjqTmE4OiCq	MXzEUXNQ	M2ThUmlEPTB;MUCg{txO	MkfWNlM5PDRyM{i=
MDA-MB-231	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX36d5F7OTBizszN	NYLyfIFZPzJiaB?=	M{[yT2ROW09?	MnnwTWM2OD1zMDFOwG0>	M1nwOFI{QDR2MEO4
SW756	NWTuTYZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\kNVAh\|ryP	NHWzV444OiCq	M3u1U2ROW09?	M4nxeGlEPTB;MUCg{txO	MVWyN\|g1PDB\|OB?=
SW-837	M{fwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nyNVExKM7:TR?=	NFWwUos4OiCq	M{TqWmROW09?	MV7JR\|UxRTFyIN88US=>	NVj6U\|A3OjN6NESwN\|g>
UMUC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXWxNEDPxE1?	MYq3NkBp	MVTEUXNQ	M1rVW2lEPTB;MUCg{txO	NFTWPJEzOzh2NECzPC=>
LS-174T	NF;QbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LjXlExKM7:TR?=	Mmn0O\|IhcA>?	M4HtWmROW09?	NInFPG9KSzVyPUGwJO69VQ>?	NF\ocnEzOzh2NECzPC=>
A549	NEnMb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S0OVExKM7:TR?=	MmPPO\|IhcA>?	MV3EUXNQ	M2e5dGlEPTB;MUCg{txO	M1fQSFI{QDR2MEO4
SHP-77	M{XDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nPd\|ExKM7:TR?=	M3THflczKGh?	Mn3hSG1UVw>?	MWTJR\|UxRTFyIN88US=>	M{jtZlI{QDR2MEO4
SW480	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{juV\|ExKM7:TR?=	M3q2bVczKGh?	NWXmcIpbTE2VTx?=	NULV[JNZUUN3ME2xNEDPxE1?	M1;OT\|I{QDR2MEO4
DLD-1	M3Xpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHS4ZXgyOCEQvF2=	MWe3NkBp	MmP0SG1UVw>?	M{ezbmlEPTB;MUCg{txO	M1qzT\|I{QDR2MEO4
HCT-116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIm2S\|kyOCEQvF2=	NYjJXWlmPzJiaB?=	NH;DVo5FVVOR	MnjNTWM2OD1zMDFOwG0>	NFPGcG0zOzh2NECzPC=>
NCI-H747	M{H2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vQd\|ExKM7:TR?=	M1f2W\|czKGh?	M4jJV2ROW09?	MUTJR\|UxRTFyIN88US=>	MmnPNlM5PDRyM{i=
T-84	NYW5SoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\mNVAh\|ryP	NFHYSWw4OiCq	M3z4VWROW09?	MkTJTWM2OD1zMDFOwG0>	M3fSWlI{QDR2MEO4
NCI-H460	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{H2d\|ExKM7:TR?=	MX[3NkBp	MULEUXNQ	NF23cGhKSzVyPUGwJO69VQ>?	NUjyelQ5OjN6NESwN\|g>
Calu-6	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLENVAh\|ryP	MorUO\|IhcA>?	MYrEUXNQ	MmHHTWM2OD1zMDFOwG0>	MojtNlM5PDRyM{i=
HCC-2998	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmr4NVAh\|ryP	Ml\rO\|IhcA>?	MXrEUXNQ	MUXJR\|UxRTFyIN88US=>	MmPNNlM5PDRyM{i=
LS1034	NFHnSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnJepQyOCEQvF2=	Mnm5O\|IhcA>?	NV;RZpVOTE2VTx?=	NGfVV\|ZKSzVyPUGwJO69VQ>?	MYGyN\|g1PDB\|OB?=
CHP-212	NUK2[3dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2D2OlExKM7:TR?=	MVm3NkBp	M2Hic2ROW09?	MUnJR\|UxRTFyIN88US=>	MWGyN\|g1PDB\|OB?=
SK-N-AS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:xNEDPxE1?	NEm3WWQ4OiCq	NEHKVmNFVVOR	NEiyb5VKSzVyPUGwJO69VQ>?	M{PMclI{QDR2MEO4
BFTC-905	NIfOWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLXSZRROTBizszN	NXTR[mpJPzJiaB?=	NYC2ZYh3TE2VTx?=	NYe2Vpk4UUN3ME2xNEDPxE1?	NVTqXoNvOjN6NESwN\|g>
HuT78	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWqxNEDPxE1?	MlPSO\|IhcA>?	NV7Ic4NvTE2VTx?=	NEjP[HpKSzVyPUWyJI5O	MXOyN\|g1PDB\|OB?=
RPMI-8226	NY\r[I1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTCe2J2OTBizszN	NUjDTXZ5PzJiaB?=	MmS5SG1UVw>?	NVPSPFhPUUN3ME2yOlMhdk1?	MWGyN\|g1PDB\|OB?=
BC-3	NYDJe2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXmRo5[OTBizszN	MnjCO\|IhcA>?	M3HzPWROW09?	MkLxTWM2OD1{N{egcm0>	NWjGVHR{OjN6NESwN\|g>
ACHN	M1ryW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW[xNEDPxE1?	M3;Se\|czKGh?	MnS5SG1UVw>?	MXPJR\|UxRTJ7NDDuUS=>	MmTkNlM5PDRyM{i=
JRT3-T35	NWLBNIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DwPVExKM7:TR?=	MV63NkBp	MmjUSG1UVw>?	M1vC[mlEPTB;Mkm1JI5O	MW[yN\|g1PDB\|OB?=
SK-MES-1	M1PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1voUlExKM7:TR?=	MlfHO\|IhcA>?	NH7GO2xFVVOR	NImzUFJKSzVyPUOyPUBvVQ>?	NX3DbHFpOjN6NESwN\|g>
CESS	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfpO2kyOCEQvF2=	MWO3NkBp	NFLKXHhFVVOR	M1vsSGlEPTB;NEm3JI5O	M4fGclI{QDR2MEO4
H4	NYPJZWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPBO4hlOTBizszN	MmTRO\|IhcA>?	MYjEUXNQ	MnezTWM2OD14MUmgcm0>	M4TUW\|I{QDR2MEO4
BC-1	M3ixemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXH1em9WOTBizszN	M1TxWVczKGh?	NXjabZlQTE2VTx?=	Moq0TWM2OD15MESgcm0>	M2rlcFI{QDR2MEO4
DB	NEn2WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17tbFExKM7:TR?=	M4jwO\|czKGh?	NH61U\|VFVVOR	M1P2XmlEPTB;OEezJI5O	NEfQb44zOzh2NECzPC=>
RPMI-6666	M{LX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3lNVAh\|ryP	MUC3NkBp	NULFNWRvTE2VTx?=	MnLGTWM2OD17Mkigcm0>	MVyyN\|g1PDB\|OB?=
MC/CAR	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jiWlExKM7:TR?=	MUe3NkBp	MlTuSG1UVw>?	NEK0eYpKSzVyPUGuNFAzKM7:TR?=	NWrie3dDOjN6NESwN\|g>
SNU-1	NGriTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DTdVExKM7:TR?=	NIDmbHo4OiCq	MUnEUXNQ	MWjJR\|UxRTFwNUCxJO69VQ>?	MVKyN\|g1PDB\|OB?=
CEM/C1	M2fvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzofXAyOCEQvF2=	NF\aZoI4OiCq	NUH2T3NQTE2VTx?=	M4jGPGlEPTB;MT63O\|Mh\|ryP	NFLtNFUzOzh2NECzPC=>
GDM-1	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnENVAh\|ryP	NYnUVJNtPzJiaB?=	M3nrOWROW09?	MkTzTWM2OD1zLkm5O{DPxE1?	MY[yN\|g1PDB\|OB?=
HT-1080	NWrlbGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLlfFN4OTBizszN	Mme1O\|IhcA>?	NUjlUI9UTE2VTx?=	MVnJR\|UxRTJwMEC0JO69VQ>?	MYeyN\|g1PDB\|OB?=
HL-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNEDPxE1?	NELYUJU4OiCq	MYjEUXNQ	MmjJTWM2OD1{LkG3PEDPxE1?	NUfBTpVROjN6NESwN\|g>
C3A	M1zDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n1SVExKM7:TR?=	NV3GOoU{PzJiaB?=	MlHSSG1UVw>?	MYnJR\|UxRTVwNEG0JO69VQ>?	M{TD[FI{QDR2MEO4
MES-SA	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLXe5kyOCEQvF2=	NXztUpFEPzJiaB?=	MWHEUXNQ	MXHJR\|UxRTZwOUi5JO69VQ>?	M4jNd\|I{QDR2MEO4
22Rv1	NFnPUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zBNlExKM7:TR?=	NYjwNohWPzJiaB?=	M2jtemROW09?	NXLEVWN2UUN3ME2xNEDPxE1?	MlTRNlM5PDRyM{i=
647-V	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjleG8yOCEQvF2=	MVy3NkBp	NW\JWFhCTE2VTx?=	NYTsd3Y4UUN3ME2xNEDPxE1?	M3flOlI{QDR2MEO4
786-O	M{CyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLWTYQyOCEQvF2=	MVK3NkBp	M3PtNWROW09?	M{SyWWlEPTB;MUCg{txO	M4W2d\|I{QDR2MEO4
A172	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K3R\|ExKM7:TR?=	NYPIOHoxPzJiaB?=	MXLEUXNQ	NHrwNWZKSzVyPUGwJO69VQ>?	M3zGdFI{QDR2MEO4
A204	NX:5SmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzvUHZDOTBizszN	NF6yUZA4OiCq	M2LlemROW09?	NUS5O4ZwUUN3ME2xNEDPxE1?	NEPKUWczOzh2NECzPC=>
A427	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XPZVExKM7:TR?=	M2HmdlczKGh?	M3ztS2ROW09?	MkjuTWM2OD1zMDFOwG0>	NX;LOIxvOjN6NESwN\|g>
A431	NUe1PXNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2CyOVExKM7:TR?=	MnLKO\|IhcA>?	NYLXfpoyTE2VTx?=	MXzJR\|UxRTFyIN88US=>	M2P3NFI{QDR2MEO4
A2780	NIDJd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LmR\|ExKM7:TR?=	MV[3NkBp	NGfvTmNFVVOR	M4WwVmlEPTB;MUCg{txO	M120elI{QDR2MEO4
ARH-77	M3LjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLaRYNHOTBizszN	NYDYXIx5PzJiaB?=	NIHBW3JFVVOR	MnW1TWM2OD1zMDFOwG0>	M4\j[VI{QDR2MEO4
Be(2)C	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3tZYdtOTBizszN	M1n6c\|czKGh?	M16xbGROW09?	NHrIdZRKSzVyPUGwJO69VQ>?	M3zZd\|I{QDR2MEO4
BT-20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuxNEDPxE1?	M4nke\|czKGh?	NXLhZmFKTE2VTx?=	MXTJR\|UxRTFyIN88US=>	MYKyN\|g1PDB\|OB?=
BxPc3	NYDo[lhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PQblExKM7:TR?=	M3P5O\|czKGh?	NV\kVFhwTE2VTx?=	NH;3OHdKSzVyPUGwJO69VQ>?	NHnwcHMzOzh2NECzPC=>
C-4 I	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[wRlQyOCEQvF2=	NUHubIFiPzJiaB?=	M1PBcmROW09?	NYr5e2t3UUN3ME2xNEDPxE1?	NXTFTYRWOjN6NESwN\|g>
C33A	NIH0VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrrNVAh\|ryP	M3HZZVczKGh?	MVfEUXNQ	NVW3WVdTUUN3ME2xNEDPxE1?	NFz5ZpMzOzh2NECzPC=>
CAL-27	M{PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjVeGFPOTBizszN	M4fifFczKGh?	MmOwSG1UVw>?	MonVTWM2OD1zMDFOwG0>	NWPNRlF[OjN6NESwN\|g>
CAL-62	M{TMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKxNEDPxE1?	NV3sU2J5PzJiaB?=	NUTLdJlITE2VTx?=	Ml;oTWM2OD1zMDFOwG0>	NHizU5ozOzh2NECzPC=>
Calu-3	NGG3XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXSxNEDPxE1?	NEDFU4E4OiCq	MXzEUXNQ	NGrhOmVKSzVyPUGwJO69VQ>?	NHnnTY4zOzh2NECzPC=>
CaOV3	M3G2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNEDPxE1?	NFHidpU4OiCq	MVnEUXNQ	MVrJR\|UxRTFyIN88US=>	MmK4NlM5PDRyM{i=
CGTHW1	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPBNVAh\|ryP	NUK3eW9VPzJiaB?=	MUjEUXNQ	NEj0XHdKSzVyPUGwJO69VQ>?	MnvrNlM5PDRyM{i=
CHL-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmmyNVAh\|ryP	MkO5O\|IhcA>?	MXTEUXNQ	MkXCTWM2OD1zMDFOwG0>	MVeyN\|g1PDB\|OB?=
Colo320DM	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13OS\|ExKM7:TR?=	MX[3NkBp	MXnEUXNQ	MYLJR\|UxRTFyIN88US=>	MYGyN\|g1PDB\|OB?=
Colo704	NH;ofYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXkRXh[OTBizszN	Mn7EO\|IhcA>?	NWTOSm5xTE2VTx?=	NYLKTGFPUUN3ME2xNEDPxE1?	M1uwWFI{QDR2MEO4
COR-L23	M4fmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4KzWlExKM7:TR?=	MYS3NkBp	MmLDSG1UVw>?	NVjBTlV3UUN3ME2xNEDPxE1?	MUiyN\|g1PDB\|OB?=
CRO-AP2	M{nuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVm3dnpTOTBizszN	MkHCO\|IhcA>?	NYHLPWRWTE2VTx?=	MVvJR\|UxRTFyIN88US=>	MmX5NlM5PDRyM{i=
Daudi	NUH1b\|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r6VFExKM7:TR?=	MlrsO\|IhcA>?	MnOzSG1UVw>?	M1jHfmlEPTB;MUCg{txO	NVrJT45TOjN6NESwN\|g>
DOTC 24510	NUHUTXFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfVNVAh\|ryP	MWm3NkBp	MofTSG1UVw>?	M3O2SmlEPTB;MUCg{txO	MnTpNlM5PDRyM{i=
DU-145	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzmNVAh\|ryP	M3XlfFczKGh?	MlHXSG1UVw>?	MWjJR\|UxRTFyIN88US=>	NIPzeoIzOzh2NECzPC=>
EB-3	NUnxWZBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj5fIdLOTBizszN	MXq3NkBp	MYLEUXNQ	M2eye2lEPTB;MUCg{txO	NFjZV5MzOzh2NECzPC=>
EFM-19	NEPtPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXSxXWoxOTBizszN	NWXRU3dJPzJiaB?=	MkL2SG1UVw>?	MnXVTWM2OD1zMDFOwG0>	MmDWNlM5PDRyM{i=
EKVX	M1PBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7yNVAh\|ryP	NX\qVVc{PzJiaB?=	NXz3NWZJTE2VTx?=	NFTzTIVKSzVyPUGwJO69VQ>?	MUKyN\|g1PDB\|OB?=
FaDu	NFTNNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\mclYyOCEQvF2=	NF\nXYc4OiCq	MkLESG1UVw>?	NUe3PZlIUUN3ME2xNEDPxE1?	NX;2cZVVOjN6NESwN\|g>
G401	NXvme3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mor4NVAh\|ryP	MXu3NkBp	MUTEUXNQ	MkfWTWM2OD1zMDFOwG0>	MVuyN\|g1PDB\|OB?=
HCC-70	MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPtNVAh\|ryP	NVLjVJVpPzJiaB?=	M{j6[GROW09?	MXTJR\|UxRTFyIN88US=>	NY\RPHZLOjN6NESwN\|g>
HCC-1954	NGDl[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	M{TlSFczKGh?	NWTtOZN4TE2VTx?=	MmfKTWM2OD1zMDFOwG0>	M1;hflI{QDR2MEO4
Hela	NFizb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDQNVAh\|ryP	M{D6SVczKGh?	MYrEUXNQ	MmLzTWM2OD1zMDFOwG0>	M2rOWVI{QDR2MEO4
Hep3B	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHHNVAh\|ryP	M3;i[FczKGh?	NFSzcXBFVVOR	NYXpe5Q6UUN3ME2xNEDPxE1?	MV:yN\|g1PDB\|OB?=
HMCB	NX;1[GNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3j1XVExKM7:TR?=	MXG3NkBp	M2TwOmROW09?	MWrJR\|UxRTFyIN88US=>	M2PqdFI{QDR2MEO4
HN5	NUC3bId1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmxNEDPxE1?	MWC3NkBp	NWnUXZQ4TE2VTx?=	MYHJR\|UxRTFyIN88US=>	MmLvNlM5PDRyM{i=
HOS	NFHvR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoKxNVAh\|ryP	MYW3NkBp	Ml3YSG1UVw>?	MV\JR\|UxRTFyIN88US=>	M321dFI{QDR2MEO4
HPAF-II	NGj2ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj6VoIyOCEQvF2=	M1;LfFczKGh?	Ml\MSG1UVw>?	M360XGlEPTB;MUCg{txO	NF;kVG8zOzh2NECzPC=>
Hs746.T	NFHVcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlP1NVAh\|ryP	Mn3aO\|IhcA>?	MoXhSG1UVw>?	NX[zRVF{UUN3ME2xNEDPxE1?	NHyzUnIzOzh2NECzPC=>
HT	M3HENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPTNVAh\|ryP	MYq3NkBp	MoPJSG1UVw>?	NEXyUpdKSzVyPUGwJO69VQ>?	NVvFUJFJOjN6NESwN\|g>
HT-3	M33tVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vaUVExKM7:TR?=	MYC3NkBp	NXHOZWc2TE2VTx?=	MlXRTWM2OD1zMDFOwG0>	MlzXNlM5PDRyM{i=
HuNS-1	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi4bWx5OTBizszN	Mn\MO\|IhcA>?	NITLS2FFVVOR	NITzZ4NKSzVyPUGwJO69VQ>?	MmHzNlM5PDRyM{i=
IGROV1	NIDOb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zQZ\|ExKM7:TR?=	MknOO\|IhcA>?	NIfB[m1FVVOR	NVLpcoFoUUN3ME2xNEDPxE1?	M{fYelI{QDR2MEO4
J82	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n1ZlExKM7:TR?=	M{nmTVczKGh?	NIDqV5NFVVOR	NFLwc41KSzVyPUGwJO69VQ>?	MnTtNlM5PDRyM{i=
JM1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYSxNEDPxE1?	M4\0W\|czKGh?	MY\EUXNQ	M{nHXGlEPTB;MUCg{txO	NYC5W5Q6OjN6NESwN\|g>
Kato III	NWTZXnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXyxNEDPxE1?	NUfxfXBYPzJiaB?=	NEnqSIpFVVOR	NWWz[Wx{UUN3ME2xNEDPxE1?	M{HiZVI{QDR2MEO4
KHOS-240S	NUjlb4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHLVZhbOTBizszN	M1fVZ\|czKGh?	MV7EUXNQ	M2rzb2lEPTB;MUCg{txO	NWfQV4JVOjN6NESwN\|g>
KM-12	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxNEDPxE1?	MofXO\|IhcA>?	NWDVOXRoTE2VTx?=	MXnJR\|UxRTFyIN88US=>	NFSwZY4zOzh2NECzPC=>
KPL-1	NVnh[WtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrmfJZxOTBizszN	Mk\oO\|IhcA>?	NVzFSGQ3TE2VTx?=	NY\MSYFiUUN3ME2xNEDPxE1?	MlS1NlM5PDRyM{i=
KYSE-30	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rKe\|ExKM7:TR?=	NHP4Wmo4OiCq	MnjRSG1UVw>?	NUfQRWtLUUN3ME2xNEDPxE1?	NYTtcVhPOjN6NESwN\|g>
LNCaP	M4e1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7jR3RqOTBizszN	M2iyOFczKGh?	MYjEUXNQ	M4TCWmlEPTB;MUCg{txO	NU\nOFk1OjN6NESwN\|g>
MCF-7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfQNVAh\|ryP	NHzzXlM4OiCq	Mn[ySG1UVw>?	Moj0TWM2OD1zMDFOwG0>	NGr6[WEzOzh2NECzPC=>
MC-IXC	NGPkcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY[xNEDPxE1?	M4HPd\|czKGh?	NU[zfIo{TE2VTx?=	Mke5TWM2OD1zMDFOwG0>	MV:yN\|g1PDB\|OB?=
MDA-MB-175 VII	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzGNVAh\|ryP	NWK0d\|dIPzJiaB?=	NUS2TokxTE2VTx?=	MXPJR\|UxRTFyIN88US=>	Mn;zNlM5PDRyM{i=
MDA-MB-468	NYXj[\|V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nlXVExKM7:TR?=	MojPO\|IhcA>?	MkjhSG1UVw>?	NHjXfmdKSzVyPUGwJO69VQ>?	MnfKNlM5PDRyM{i=
MiaPaCa	M3HLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf1No4yOCEQvF2=	NYn4OphQPzJiaB?=	NVLSeXRETE2VTx?=	NHfEfGFKSzVyPUGwJO69VQ>?	M1jUfFI{QDR2MEO4
Molt-4	NUG5cmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFX2TpoyOCEQvF2=	MofsO\|IhcA>?	M1nYeWROW09?	NHTWXFZKSzVyPUGwJO69VQ>?	NGWzOI4zOzh2NECzPC=>
NCI-ADR/RES	NHHl[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfzNVAh\|ryP	MkT0O\|IhcA>?	NFr3Z5lFVVOR	M1;sUmlEPTB;MUCg{txO	M33FU\|I{QDR2MEO4
NCI-H69	NVPrNVhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nQXlExKM7:TR?=	MnzaO\|IhcA>?	M{XQeWROW09?	NEXWdFRKSzVyPUGwJO69VQ>?	NEfENpYzOzh2NECzPC=>
NCI-H82	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGC2emoyOCEQvF2=	NF\OXGI4OiCq	MV\EUXNQ	NUXVXIRKUUN3ME2xNEDPxE1?	MkjuNlM5PDRyM{i=
NCI-N87	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	MWm3NkBp	MYHEUXNQ	NVGzNlZiUUN3ME2xNEDPxE1?	NYG3[VdsOjN6NESwN\|g>
NCI-H146	NV60N4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPaeocyOCEQvF2=	NYS5cHRRPzJiaB?=	MVfEUXNQ	NXX0bHFtUUN3ME2xNEDPxE1?	MonnNlM5PDRyM{i=
NCI-H157	M2XSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmxNEDPxE1?	MonqO\|IhcA>?	M3rMSmROW09?	MWfJR\|UxRTFyIN88US=>	M3zlR\|I{QDR2MEO4
NCI-H187	NVjyfpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXEOYZoOTBizszN	M2PjeVczKGh?	MlXvSG1UVw>?	NXfBcIhVUUN3ME2xNEDPxE1?	NE\tNVMzOzh2NECzPC=>
NCI-H209	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGxNEDPxE1?	M13COFczKGh?	NWPyZ\|U3TE2VTx?=	MmjETWM2OD1zMDFOwG0>	NYHSOYFyOjN6NESwN\|g>
NCI-H226	M2DTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYri[2ptOTBizszN	M3n4d\|czKGh?	MUTEUXNQ	NYXWRYZ4UUN3ME2xNEDPxE1?	NIHj[3YzOzh2NECzPC=>
NCI-H292	M4TGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;NV5NtOTBizszN	MV63NkBp	MmrISG1UVw>?	MVzJR\|UxRTFyIN88US=>	M2ToSFI{QDR2MEO4
NCI-H322	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P2flExKM7:TR?=	MofyO\|IhcA>?	MV7EUXNQ	Ml7OTWM2OD1zMDFOwG0>	MYqyN\|g1PDB\|OB?=
NCI-H358	NGDnRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PPWVExKM7:TR?=	MV23NkBp	MVXEUXNQ	M1j3cmlEPTB;MUCg{txO	MWKyN\|g1PDB\|OB?=
NCI-H520	NYjaSJh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvURmkyOCEQvF2=	NG\MTnA4OiCq	MWXEUXNQ	MYTJR\|UxRTFyIN88US=>	M3\ZZ\|I{QDR2MEO4
NCI-H526	M2TRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Tae\|ExKM7:TR?=	NVnPdJRMPzJiaB?=	NWfjOYRYTE2VTx?=	MWjJR\|UxRTFyIN88US=>	NYiyW5BNOjN6NESwN\|g>
NCI-H630	NH7h[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTTTGV[OTBizszN	MmTTO\|IhcA>?	NWGxc5R5TE2VTx?=	NH3pRmdKSzVyPUGwJO69VQ>?	MVKyN\|g1PDB\|OB?=
NCI-H661	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVGxNEDPxE1?	M1uw[\|czKGh?	MojESG1UVw>?	MV7JR\|UxRTFyIN88US=>	MWWyN\|g1PDB\|OB?=
NCI-H716	NYXtNXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmxNEDPxE1?	MmD5O\|IhcA>?	M{LBTWROW09?	NWXJWolpUUN3ME2xNEDPxE1?	M4ftSFI{QDR2MEO4
NCI-H1563	NH25XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHX[XhCOTBizszN	NEXEeWg4OiCq	NXnXOJFZTE2VTx?=	MmmwTWM2OD1zMDFOwG0>	MmDZNlM5PDRyM{i=
NCI-H1792	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjZN4IyOCEQvF2=	M2HkOFczKGh?	M2O1d2ROW09?	NVfuTJFKUUN3ME2xNEDPxE1?	MWCyN\|g1PDB\|OB?=
NCI-H2030	M3XO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnl[mVmOTBizszN	M4XtSlczKGh?	NGS4R41FVVOR	NFq2ZVRKSzVyPUGwJO69VQ>?	MXeyN\|g1PDB\|OB?=
NCI-H2052	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2xNEDPxE1?	NVrkUnJVPzJiaB?=	NFvCWYNFVVOR	M3zOVWlEPTB;MUCg{txO	M2rkUVI{QDR2MEO4
NCI-H2122	NEfYZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnCcppWOTBizszN	Mom2O\|IhcA>?	M2T6fWROW09?	NHvwbJVKSzVyPUGwJO69VQ>?	NXvheW5DOjN6NESwN\|g>
NCI-H2228	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LMRlExKM7:TR?=	M3v5UFczKGh?	MWPEUXNQ	NFLjdIRKSzVyPUGwJO69VQ>?	MoLGNlM5PDRyM{i=
OE-19	MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjzTmZUOTBizszN	NFG1TpM4OiCq	NGn6cmVFVVOR	MXrJR\|UxRTFyIN88US=>	NGrDcIQzOzh2NECzPC=>
OE-21	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[xU48yOCEQvF2=	M4\zelczKGh?	MV7EUXNQ	MlzTTWM2OD1zMDFOwG0>	NV3QW5N[OjN6NESwN\|g>
OE-33	M2C4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LWelExKM7:TR?=	M4PZO\|czKGh?	Mnj4SG1UVw>?	NXK0XGtsUUN3ME2xNEDPxE1?	NXzrSpNxOjN6NESwN\|g>
OVCAR-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInTUoQyOCEQvF2=	MXi3NkBp	NUnONmhHTE2VTx?=	NWLpdoV2UUN3ME2xNEDPxE1?	NFXEdIYzOzh2NECzPC=>
OVCAR-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVSxNEDPxE1?	M16wflczKGh?	NFe3NoZFVVOR	MoD6TWM2OD1zMDFOwG0>	NYPRUIpUOjN6NESwN\|g>
OVCAR-5	MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e5NVExKM7:TR?=	M{HOXlczKGh?	MVLEUXNQ	NIfzemdKSzVyPUGwJO69VQ>?	M2TUZlI{QDR2MEO4
P3HR-1	M2\Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	M3HJOVczKGh?	NYDaNodRTE2VTx?=	MUnJR\|UxRTFyIN88US=>	NELtdWYzOzh2NECzPC=>
PC-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXENVAh\|ryP	Mlr3O\|IhcA>?	Mn7NSG1UVw>?	NWXyTFdjUUN3ME2xNEDPxE1?	MnXVNlM5PDRyM{i=
Raji	M4fkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHvNVAh\|ryP	NVzaOYU2PzJiaB?=	NH3rVWxFVVOR	MmDtTWM2OD1zMDFOwG0>	MonmNlM5PDRyM{i=
RD	M1HlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37tWFExKM7:TR?=	MUO3NkBp	NX;HNpFNTE2VTx?=	NHH1SmxKSzVyPUGwJO69VQ>?	NVftTJZjOjN6NESwN\|g>
RD-ES	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzkTI1nOTBizszN	MX63NkBp	NEjxXoFFVVOR	NGDXSI1KSzVyPUGwJO69VQ>?	NFTrcFczOzh2NECzPC=>
RL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknkNVAh\|ryP	MYO3NkBp	NV3X[pZlTE2VTx?=	MmXJTWM2OD1zMDFOwG0>	NGT6WnAzOzh2NECzPC=>
SaOS2	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\2UlExKM7:TR?=	NFf0[pk4OiCq	MknuSG1UVw>?	M3q4VGlEPTB;MUCg{txO	MmTLNlM5PDRyM{i=
SCC-9	NHLxcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLqVVcyOCEQvF2=	MU[3NkBp	NW\3WJM1TE2VTx?=	NITKW3pKSzVyPUGwJO69VQ>?	NVHXeHI6OjN6NESwN\|g>
SCC-12	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf3WGU5OTBizszN	MWO3NkBp	NGHQT4dFVVOR	M4PNc2lEPTB;MUCg{txO	MnjINlM5PDRyM{i=
SCC-13	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TSTlExKM7:TR?=	NEOyfIs4OiCq	Mm[5SG1UVw>?	M4HoOmlEPTB;MUCg{txO	MYOyN\|g1PDB\|OB?=
SCC-15	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\jUlEyOCEQvF2=	NFLPUlE4OiCq	NG\VN\|lFVVOR	MoXLTWM2OD1zMDFOwG0>	NHrpWmYzOzh2NECzPC=>
SCC-25	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\XNVAh\|ryP	MoDMO\|IhcA>?	NH3GPVVFVVOR	MXTJR\|UxRTFyIN88US=>	M1fK[FI{QDR2MEO4
SCLC-3	M1XJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Pj[VExKM7:TR?=	NH;DcGQ4OiCq	MYXEUXNQ	NF\RTIhKSzVyPUGwJO69VQ>?	MmrlNlM5PDRyM{i=
SF-268	M1z5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFryfmMyOCEQvF2=	M2rUV\|czKGh?	M3G3PWROW09?	MnrRTWM2OD1zMDFOwG0>	MliyNlM5PDRyM{i=
SF-295	NIXHTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\jU\|ExKM7:TR?=	NVK5XVdxPzJiaB?=	NF\XfFFFVVOR	MmD2TWM2OD1zMDFOwG0>	NV[xPHlROjN6NESwN\|g>
SJRH30	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	M1G3eFczKGh?	MmKySG1UVw>?	NVv0PGtrUUN3ME2xNEDPxE1?	M3X1c\|I{QDR2MEO4
SK-BR-3	NEPUdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvpNpAyOCEQvF2=	MXm3NkBp	M1npOmROW09?	MnzRTWM2OD1zMDFOwG0>	M3SyZlI{QDR2MEO4
SK-LMS-1	NXTmXml[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M331e\|ExKM7:TR?=	M33pUlczKGh?	MYDEUXNQ	M2rJOmlEPTB;MUCg{txO	M4XGRVI{QDR2MEO4
SK-N-DZ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHrZZcyOCEQvF2=	NYXGdJhUPzJiaB?=	MXfEUXNQ	M3vpTGlEPTB;MUCg{txO	NWPWVGxZOjN6NESwN\|g>
SK-N-F1	M1[5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLpNVAh\|ryP	MX[3NkBp	NIe0PVRFVVOR	NUPIWGFnUUN3ME2xNEDPxE1?	MVeyN\|g1PDB\|OB?=
SKOV-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjuWFdyOTBizszN	M3fkTVczKGh?	M2O0dmROW09?	MUTJR\|UxRTFyIN88US=>	MXuyN\|g1PDB\|OB?=
SK-UT-1	NFHBclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn3UYxkOTBizszN	MXu3NkBp	Ml\ESG1UVw>?	M1zibGlEPTB;MUCg{txO	M{HyclI{QDR2MEO4
SN12C	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWixNEDPxE1?	MlrlO\|IhcA>?	M1HkdmROW09?	NYHoTXpEUUN3ME2xNEDPxE1?	M3fieVI{QDR2MEO4
SNB-19	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLMNVAh\|ryP	Ml3EO\|IhcA>?	M1q0emROW09?	MmToTWM2OD1zMDFOwG0>	MUSyN\|g1PDB\|OB?=
SNU-5	NV7TWINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	MVS3NkBp	NWTPOFF6TE2VTx?=	MUjJR\|UxRTFyIN88US=>	NH\JXogzOzh2NECzPC=>
SNU-16	M{OyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGL0eYsyOCEQvF2=	NHPQR5M4OiCq	MWjEUXNQ	MoLDTWM2OD1zMDFOwG0>	M1rCWVI{QDR2MEO4
SNU-398	NH3lO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXmT5dOOTBizszN	MoW4O\|IhcA>?	NYTPNWxsTE2VTx?=	NHvDRppKSzVyPUGwJO69VQ>?	M3rLWVI{QDR2MEO4
SNU-449	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;i[IUyOCEQvF2=	MYS3NkBp	NF3HbGlFVVOR	M2OwdWlEPTB;MUCg{txO	NXnLfml4OjN6NESwN\|g>
SR	NVG0NIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3mXIYyOCEQvF2=	MorhO\|IhcA>?	NXjq[oNtTE2VTx?=	MVLJR\|UxRTFyIN88US=>	MkDENlM5PDRyM{i=
ST486	MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOxNEDPxE1?	MVG3NkBp	MV\EUXNQ	MXrJR\|UxRTFyIN88US=>	M1G3bFI{QDR2MEO4
SW579	NFv4SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfsbXdLOTBizszN	MnvIO\|IhcA>?	NYHBc41wTE2VTx?=	M4PnNWlEPTB;MUCg{txO	MYmyN\|g1PDB\|OB?=
SW684	NUS0ZlRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfCWI8yOCEQvF2=	NFnFXYQ4OiCq	NULkUmhbTE2VTx?=	MorXTWM2OD1zMDFOwG0>	MX[yN\|g1PDB\|OB?=
SW-780	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	NXz3OG1ZPzJiaB?=	MV;EUXNQ	NEjQRWlKSzVyPUGwJO69VQ>?	NWT4OlR2OjN6NESwN\|g>
SW900	NIrpVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\wNVAh\|ryP	MVu3NkBp	MkPySG1UVw>?	MWrJR\|UxRTFyIN88US=>	MkfNNlM5PDRyM{i=
SW1088	NHnEPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlX3NVAh\|ryP	M1:yVFczKGh?	NUizb3lVTE2VTx?=	MWnJR\|UxRTFyIN88US=>	MVmyN\|g1PDB\|OB?=
SW1463	NXTPe3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\MNVAh\|ryP	NIj2WYY4OiCq	M4jjTGROW09?	NGrQRldKSzVyPUGwJO69VQ>?	NYG1PY1zOjN6NESwN\|g>
SW1990	M4qw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfCNYEyOCEQvF2=	NGXBSmg4OiCq	M1zJS2ROW09?	NX3wd5NrUUN3ME2xNEDPxE1?	NHjWbo8zOzh2NECzPC=>
T47D	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonnNVAh\|ryP	MmnMO\|IhcA>?	MYHEUXNQ	MV7JR\|UxRTFyIN88US=>	NWj3fmtqOjN6NESwN\|g>
TE381.T	M1u1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HifFExKM7:TR?=	M3;iU\|czKGh?	NF3vSolFVVOR	NFzPXGRKSzVyPUGwJO69VQ>?	NVu0O5RLOjN6NESwN\|g>
TK-10	NUT2W2pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnncY5yOTBizszN	MnHZO\|IhcA>?	MX\EUXNQ	NIjGVYFKSzVyPUGwJO69VQ>?	NV;kemMzOjN6NESwN\|g>
U2OS	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP0WXUyOCEQvF2=	NWfSTnJZPzJiaB?=	NHvRVHJFVVOR	M{DyemlEPTB;MUCg{txO	MVWyN\|g1PDB\|OB?=
U251	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xNEDPxE1?	M1fXO\|czKGh?	MmP1SG1UVw>?	M170VmlEPTB;MUCg{txO	MnLGNlM5PDRyM{i=
UACC-812	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxNEDPxE1?	NWnh[pFWPzJiaB?=	M2HEfmROW09?	MkexTWM2OD1zMDFOwG0>	NUHGNGt1OjN6NESwN\|g>
YAPC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\rNVAh\|ryP	MUi3NkBp	NWrvdI9KTE2VTx?=	NU\1PJNSUUN3ME2xNEDPxE1?	MVmyN\|g1PDB\|OB?=
ZR-75-1	M4\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXThdHdUOTBizszN	M{fwW\|czKGh?	MUnEUXNQ	MnjBTWM2OD1zMDFOwG0>	NEfpT4gzOzh2NECzPC=>
A375	NV3tO\|JvTnWwY4Tpc44h[XO\|YYm=	M2\0PFEvOiEQvF2=	NH\DflA1KGh?	MnjnSG1UVw>?	MYfJcohq[mm2aX;uJI9nKHCqb4PwbI9zgWyjdHnvckBw\iCPRVusJGVTUyxiYX7kJHM3WA>?	M4S5N\|IzOzh7NEex
YUSIT1	MnGwSpVv[3Srb36gZZN{[Xl?			M1SxcmROW09?	M{LqV5Jm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR\|UxKD5iMD61JO69VQ>?	NF:zWmozOjN6OUS3NS=>
MeWo	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MorOSG1UVw>?	MWnJR\|UxKD1iOUi3JI5O	NIXzNFEzPjBzOEWyOC=>
WiDr	MmSwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NEnIS5JFVVOR	MUnJR\|UxKD1iN{[gcm0>	M2XZ[lI3ODF6NUK0
Colo-205	MWDGeY5kfGmxbjDhd5NigQ>?	M1jTdFEh\|ryP	M{nF[VQh\A>?	NGTucpZFVVOR	M{HBOWlv\HWlZXSgZUBpcWeqbImgZ49ueGG{YXLs[UBkd22yYXP0bY9vKHCqZX7veJlx\Q>?	NIe2fmIzPTN6MUG1Ni=>
RBW-1	NEH2XWxHfW6ldHnvckBie3OjeR?=	MU[xJO69VQ>?		MV;EUXNQ	MnLKUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	NI\6TVIzPDh6NU[5NC=>
RBO-1	NEjZVJpHfW6ldHnvckBie3OjeR?=	M33XcFEh\|ryP		M{PNcWROW09?	NVvQc2pxUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	Ml3rNlQ5QDV4OUC=
RBO-2	M3\5NWZ2dmO2aX;uJIF{e2G7	Mn7FNUDPxE1?		NFHnXHRFVVOR	MWfJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	NXn6dY94OjR6OEW2PVA>
RBOW	MVXGeY5kfGmxbjDhd5NigQ>?	NUXIb\|Z6OSEQvF2=		MoCwSG1UVw>?	NUH5cI51UW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	MUCyOFg5PTZ7MB?=
M257	M1:xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrqNVAxKG6P	NVj2RVB6PzJiaB?=		MYPEc4V{KG6xdDDpcohq[mm2IIDyc4xq\mW{YYTpc44hd2ZiTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ?	M3XKRlI{OzF5NES2
LCP	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfwSXYyODBibl2=	MVG3NkBp		MofVTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=>	MWmyN\|MyPzR2Nh?=
WM266	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6wNVAxKG6P	NVjKXpJtPzJiaB?=		M3HpZWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>?	MkTGNlM{OTd2NE[=
M257	NXLPVZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3r4OFExOCCwTR?=	MlnZO\|IhcA>?		NYnC[I9GTG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	MmHNNlM{OTd2NE[=
LCP	M4K1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXqb4IzOTByIH7N	NYDkV2p[PzJiaB?=		M4rEdWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	M3XUdFI{OzF5NES2
WM266	NE\s[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfzVFBtOTByIH7N	MWq3NkBp		MVvJcohq[mm2IFXST\|EuOiCyaH;zdIhwenmuYYTpc44hcW5iV12yOlYh[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNGQhdXW2YX70ZZRqd25?	Mkn3NlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+45% PEG 300+2% Tween 80+ddH2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

Dabrafenib (GSK2118436)

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献150篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品